Drug Trial Radar · NCT07364448
A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
411
Actual
Start
Mar 12, 2026
Primary completion
Jun 22, 2026
Study completion Jun 22, 2026
Sponsor
- Lead sponsor
- Beijing Continent Pharmaceutical Co, Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- The First Hospital of Jilin University
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm study designed to collect safety data on hydronidone capsules in patients with chronic hepatitis B virus infection accompanied by liver fibrosis or fatty liver disease accompanied by liver fibrosis . Approximately 200 subjects will be enrolled, all of whom will receive hydronidone capsules three times daily, with three capsules per dose, resulting in a total daily treatment dose of 270 mg. The medication will be administered orally half an hour before meals for a total of 28 days.
Conditions
- Chronic Hepatitis B With Hepatic Fibrosis
Interventions
Hydronidone capsulesDrug
three times a day, 3 capsules each time,
Primary outcomes
What the sponsor says the trial is designed to measure.
- Any adverse events occurring in study participants following drug administration.Time frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jilin University First Hospital
Jilin City, Changchun, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.